A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Summary

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

Timeline

Start

2008-09

Primary completion

—

Completion

—

Drugs

Indications